Modeling Human Malignancy with Patient-Derived Xenograft Cancer Models
Webinar - The Jackson Laboratory, Bar Harbor, Maine, US
The April webinar series is about mouse models for pre-clinical research.
Coming in May: Advanced Mouse Modeling
Patient-derived xenograft (PDX) cancer models show great promise as preclinical models because they recapitulate the heterogeneity of human cancer. The JAX PDX program was developed in collaboration with renowned cancer hospitals to advance the course of preclinical drug development. In this webinar, you will:
Learn how more than 150 "all comers" PDX models have been established in partnership with a consortium of cancer hospitals and clinical trial teams
Appreciate how the diversity of the PDX program represents current patient demographics
See how the genetics, pathology, and treatment response of PDX tumors reflect clinical observations
Understand how patient-derived hematological cancers are modeled in the mouse
Learn about current advances that take advantage of the immunodeficient NSG mouse host
Understand how to obtain PDX models from JAX® In Vivo Pharmacology Services
Presenter: Emily Jocoy, Ph.D., Technical Information Scientist
Moderator: Kathy Snow, Ph.D., Technical Information Scientist
(Courtesy of The Jackson Laboratory campus in Bar Harbor, Maine, yourobserver.com)
Modeling Human Malignancy with Patient-Derived Xenograft Cancer Models
April 18th, 2013
Time: 10am PT / 11am MT / 12pm CT / 1pm ET
Online/Webinar
The Jackson Laboratory, Bar Harbor, Maine, US
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
